BCR-ABL1 kinase domain mutations: Methodology and clinical evaluation
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BCR-ABL1 kinase domain mutations: Methodology and clinical evaluation
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 87, Issue 3, Pages 298-304
Publisher
Wiley
Online
2011-12-17
DOI
10.1002/ajh.22272
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chronic myeloid leukemia 2011: Successes, challenges, and strategies-Proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop
- (2011) Tariq I. Mughal et al. AMERICAN JOURNAL OF HEMATOLOGY
- The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia
- (2011) T. O'Hare et al. BLOOD
- Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia
- (2011) Letizia Foroni et al. BRITISH JOURNAL OF HAEMATOLOGY
- Mutational analysis in chronic myeloid leukemia: when and what to do?
- (2011) Susan Branford et al. CURRENT OPINION IN HEMATOLOGY
- Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50?
- (2011) S. Soverini et al. ONCOLOGIST
- Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
- (2010) Elias Jabbour et al. CANCER
- Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors
- (2010) Gonzalo Manrique Arechavaleta et al. CLINICAL AND EXPERIMENTAL MEDICINE
- Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia
- (2010) Amber Fullmer et al. EXPERT OPINION ON PHARMACOTHERAPY
- Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML
- (2010) Susanne Schnittger et al. GENES CHROMOSOMES & CANCER
- Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis
- (2010) S. Soverini et al. HAEMATOLOGICA
- Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
- (2010) N. P. Shah et al. HAEMATOLOGICA
- Comprehensive Characterization of a Novel Intronic Pseudo-Exon Inserted within an e14/a2 BCR-ABL Rearrangement in a Patient with Chronic Myeloid Leukemia
- (2010) Nathalie Sorel et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Third-Generation Tyrosine Kinase Inhibitors and Beyond
- (2010) Alfonso Quintás-Cardama et al. SEMINARS IN HEMATOLOGY
- Response definitions and European Leukemianet Management recommendations
- (2009) Michele Baccarani et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
- (2009) M. C. Muller et al. BLOOD
- Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
- (2009) S. Soverini et al. BLOOD
- Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
- (2009) S. Branford et al. BLOOD
- Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
- (2009) H. Kantarjian et al. BLOOD
- Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia
- (2009) T. D. Kim et al. HAEMATOLOGICA
- A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib
- (2009) T. Ernst et al. HAEMATOLOGICA
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
- (2009) Michele Baccarani et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of BaselineBCR-ABLMutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
- (2009) Timothy Hughes et al. JOURNAL OF CLINICAL ONCOLOGY
- Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters
- (2009) A Davies et al. LEUKEMIA
- Chronic myeloid leukemia in the tyrosine kinase inhibitor era: What is the best therapy?
- (2009) Alfonso Quintás-Cardama et al. Current Oncology Reports
- Translation of the Philadelphia chromosome into therapy for CML
- (2008) B. J. Druker BLOOD
- Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors
- (2008) Dan Jones et al. CANCER
- Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib
- (2008) T. Ernst et al. HAEMATOLOGICA
- Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression
- (2008) Jamshid S. Khorashad et al. JOURNAL OF CLINICAL ONCOLOGY
- A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia
- (2008) J S Khorashad et al. JOURNAL OF CLINICAL PATHOLOGY
- ABL Kinase Domain Pseudoexon Insertion Is Not Uncommon in BCR-ABL Transcripts
- (2008) Neil B. Quigley et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Chronic Myeloid Leukemia Patients Undergoing Kinase Inhibitor Therapy
- (2008) Jennifer Laudadio et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia
- (2008) Dan Jones et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR
- (2008) O Pelz-Ackermann et al. LEUKEMIA
- Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia
- (2008) D W Sherbenou et al. LEUKEMIA
- Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR
- (2008) V G Oehler et al. LEUKEMIA
- High-resolution melt curve analysis: Initial screening for mutations in BCR-ABL kinase domain
- (2008) Kateřina Machová Poláková et al. LEUKEMIA RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started